close
close

AstraZeneca's experimental cancer drug shows no significant improvement in overall survival







AstraZeneca's experimental cancer drug shows no significant improvement in overall survival


















XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.

Reuters

AstraZeneca's experimental cancer drug shows no significant improvement in overall survival

AstraZeneca's experimental cancer drug shows no significant improvement in overall survival

23 September (Reuters) –AstraZeneca AZN.L announced on Monday that its experimental precision medicine, developed jointly with Daiichi Sankyo 4568.T did not significantly improve overall survival in patients with a certain type of breast cancer in a late-stage study.

Overall survival or OS rates in the Phase III TROPION-Breast01 trial of datopotamab deruxtecan (Dato-DXd) did not reach statistical significance, AstraZeneca said.

Reporting by Yadarisa Shabong in Bengaluru; Editing by Rashmi Aich

Disclaimer: The XM Group companies provide execution services only and provide access to our online trading platform through which individuals can view and/or use the content available on or through the website. No modification or addition to this content is intended or will be made. Access and use is always subject to the following terms: (i) General Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. The content provided therefore only represents general information. Please note in particular that the content of our online trading platform does not constitute an invitation or an offer to conclude transactions on the financial markets. Trading on financial markets carries a significant risk to your invested capital.

All materials published on our online trading platform are for educational and informational purposes only. The materials do not contain, and should not be construed as, financial, investment tax or trading advice or recommendations. In addition, the materials do not contain, and should not be construed as, a record of our trading prices, an offer or solicitation for any transactions in financial instruments or unsolicited financial marketing to you.

All third party content and the content provided by XM, as well as the opinions, news, research, analysis, prices and other information or links to third party sites provided on this website are provided “as is”. They are intended as general market commentary and do not constitute investment advice. To the extent that any content is deemed to be investment research, you must acknowledge and accept that the content has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is therefore to be regarded as a marketing communication in compliance with applicable laws and regulations. Please ensure that you have read and understood our non-independent investment research notice and risk warning in relation to the above information, which can be found here.